Our Health Library information does not replace the advice of a doctor. Please be advised that this information is made available to assist our patients to learn more about their health. Our providers may not see and/or treat all topics found herein.

etesevimab

Pronunciation: ET e SEV a mib

What is the most important information I should know about etesevimab?

The FDA has authorized emergency use of etesevimab in combination with bamlanivimab only in people with COVID-19 who are not in a hospital or using supplemental oxygen.

Etesevimab has not been approved to treat coronavirus or COVID-19.

What is etesevimab?

Etesevimab is an experimental medicine being studied for use in treating conditions caused by coronavirus. It is not yet known if etesevimab is safe and effective.

The US Food and Drug Administration (FDA) has authorized emergency use of etesevimab in combination with another medicine called bamlanivimab in people who test positive for COVID-19, to treat COVID-19 symptoms that could become severe enough to need treatment in a hospital or cause death.

Etesevimab and bamlanivimab are for use in adults and children at least 12 years old who weigh at least 88 pounds (40 kilograms).

The risk of COVID-19 symptoms becoming severe may be higher in people who:

  • are overweight;
  • have chronic kidney disease;
  • have diabetes;
  • have a weak immune system (caused by disease or by using certain medicine);
  • have sickle cell disease;
  • have a heart problem or high blood pressure;
  • have a neurodevelopmental disorder such as cerebral palsy;
  • have asthma or other chronic breathing disorder; or
  • have a tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19).

There also may be a higher risk of severe COVID-19 symptoms in pregnant women and in adults who are 65 and older.

Etesevimab and bamlanivimab have not been approved to treat coronavirus or COVID-19. However, these medicines may help prevent the need for emergency medical care or admission to a hospital because of COVID-19. Etesevimab with bamlanivimab is not authorized for use in people who are already in the hospital or receiving supplemental oxygen for COVID-19.

Etesevimab may also be used for purposes not listed in this medication guide.

What should I discuss with my healthcare provider before receiving etesevimab?

Tell your doctor if:

  • you have any allergy;
  • you have any serious or chronic disease; or
  • you are pregnant or breastfeeding.

COVID-19 is more likely to cause serious illness or death in a pregnant woman. Not all risks are known yet, but being treated with etesevimab and bamlanivimab is likely to be less harmful than being infected with COVID-19 during pregnancy.

How is etesevimab given?

Etesevimab and bamlanivimab are injected into a vein by healthcare provider.

These medicines are injected slowly over 21 to 70 minutes. You will be watched for a short time to make sure you do not have an allergic reaction.

Bamlanivimab with etesevimab is usually given as only one dose as soon as possible after you test positive for COVID-19, or within 10 days after the start of symptoms.

Being treated with etesevimab and bamlanivimab will not make you less contagious to other people. Keep using infection control methods such as self-isolation, social distancing, hand-washing, using protective face covering, disinfecting surfaces you touch a lot, and not sharing personal items with others.

These medicines also may not keep you from becoming infected with coronavirus again. Being treated with etesevimab and bamlanivimab could also affect your body's immune response to a coronavirus vaccine. Etesevimab and bamlanivimab are still being studied and all of the risks are not yet known.

What happens if I miss a dose?

Etesevimab is given with bamlanivimab in a single dose and does not have a daily dosing schedule.

What happens if I overdose?

In a medical setting an overdose would be treated quickly.

What should I avoid after receiving etesevimab?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

What are the possible side effects of etesevimab?

Get emergency medical help if you have signs of an allergic reaction: hives, itching, warmth, tingling; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection. Tell your medical caregivers right away if you have:

  • throat irritation, swelling in your face or throat;
  • fever, chills, sweating;
  • a rash or itching;
  • dizziness, a light-headed feeling (like you might pass out);
  • wheezing, shortness of breath;
  • nausea;
  • chest pain, fast or slow heartbeats, pounding in your neck or ears;
  • muscle pain; or
  • headache, change in your mental status, extreme weakness or tiredness.

Call your doctor if you have new or worsening symptoms after the infusion, such as fever, confusion, weakness, tiredness, trouble breathing, or fast or slow heartbeats.

Common side effects may include:

  • nausea;
  • dizziness; or
  • itching.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect etesevimab?

Other drugs may affect etesevimab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Where can I get more information?

Your pharmacist can provide more information about etesevimab.

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2021 Cerner Multum, Inc. Version: 2.01. Revision date: 8/13/2021.

Your use of the content provided in this service indicates that you have read, understood and agree to the End-User License Agreement, which can be accessed by End-User License Agreement, which can be accessed by clicking on this link.